Skip to content
Peptide research

Syn-Coll

Also known as Palmitoyl Tripeptide-5
Category
Skin & Cosmetic
Administration routes
Topical
Regulatory status
Cosmetic ingredient

A synthetic peptide applied to skin, marketed for firmness and fine-line reduction by signaling skin cells into collagen-production mode. Human evidence is thin, limited to small trials of modest wrinkle improvement, while deeper collagen claims rest mainly on lab reasoning. Safety data is limited, reported issues mild (dryness, occasional sensitivity). Not an approved drug in the US; it is sold as a cosmetic ingredient, subject to applicable cosmetic safety and labeling requirements.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Syn-Coll (Palmitoyl Tripeptide-5) is a synthetic 3-amino-acid peptide designed to boost your skin's natural collagen production. Developed by DSM-Firmenich, it works by mimicking a protein in your body that activates TGF-beta, one of the key signals telling skin cells to make more collagen. A fatty acid is attached to help it penetrate the skin barrier and reach the deeper layers where collagen is produced. Manufacturer data claims it is roughly 60% more effective at wrinkle reduction than the popular peptide Matrixyl.

How it works in the body

Palmitoyl Tripeptide-5 mimics thrombospondin-1, a protein that activates TGF-beta signaling. When TGF-beta is activated, it stimulates fibroblasts to produce collagen. This 'tricks' skin cells into collagen production mode, increasing skin firmness and reducing fine lines.

Research overview

Syn-Coll stimulates collagen production by activating TGF-beta signaling in skin cells, which tells fibroblasts to ramp up production of type I and type III collagen — the structural proteins that keep skin firm. It also blocks the enzymes (MMP-1 and MMP-3) that break collagen down, addressing both sides of the equation. In the manufacturer's 84-day study of 60 volunteers, Syn-Coll produced 7-12% wrinkle reduction measured by skin surface imaging, outperforming both placebo and the comparator peptide Matrixyl. A separate study of 33 women showed 77% reported improved skin firmness after 4 weeks. Large independent clinical trials testing Syn-Coll as a sole ingredient are lacking, and the cited CIR literature review does not establish a final Syn-Coll safety finding.

Who researches Syn-Coll?

Commonly researched by

  • People researching skin health and rejuvenation

    Studied for collagen synthesis, skin repair, or anti-aging skin effects.

  • People researching longevity and anti-aging interventions

    Studied for effects on aging pathways, cellular health, or lifespan extension.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Those with Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Safety & interactions

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(4)

Rated by level of concern

  • Mild skin dryness or flaking

    Low

    PMID 31134751 — https://pubmed.ncbi.nlm.nih.gov/31134751/

  • Allergic or sensitivity reaction (rare)

    Low

    PMID 34451799 — https://pubmed.ncbi.nlm.nih.gov/34451799/ ; PMID 31134751 — https://pubmed.ncbi.nlm.nih.gov/31134751/

  • Theoretical TGF-beta pathway concerns

    Theoretical

    PMID 7706271 (TSP-1/TGF-beta activation biology) — https://pubmed.ncbi.nlm.nih.gov/7706271/

  • Limited long-term safety data

    Moderate

    Evidence gap; no long-term trial located on PubMed or ClinicalTrials.gov

Interaction summary(8)

Rated by direction with this peptide

  • Microneedling / microneedle patch delivery

    SynergisticLow

    Barrier disruption markedly increases delivery of an otherwise poorly-permeating palmitoylated peptide, and the only 12-week human tolerability/efficacy data for palmitoyl tripeptide-5 come from an HA microneedle patch (PMID 31134751) — with the trade-off that intact-barrier assumptions about negligible systemic exposure (PMID 36985499) no longer hold.

    PMID 31134751 — https://pubmed.ncbi.nlm.nih.gov/31134751/ ; PMID 36985499 — https://pubmed.ncbi.nlm.nih.gov/36985499/

  • Fractional / Nd:YAG laser resurfacing (peri-procedure application)

    SynergisticTheoretical

    Picosecond- and nanosecond-domain Nd:YAG laser pretreatment enhances cutaneous delivery of cosmeceutical peptides with rapid barrier recovery (PMID 35214181) — but that study tested palmitoyl tripeptide-1, palmitoyl tripeptide-38, and copper tripeptide-1, NOT palmitoyl tripeptide-5, so any delivery boost for this peptide is an unverified extrapolation. Application onto freshly ablated skin should follow the treating clinician's protocol.

    PMID 35214181 (laser-assisted delivery of other palmitoyl tripeptides; not tripeptide-5) — https://pubmed.ncbi.nlm.nih.gov/35214181/

  • Topical retinoids (tretinoin, retinaldehyde, retinol)

    SynergisticTheoretical

    Retinoids stimulate procollagen I/III and suppress MMP-1 through a receptor pathway independent of TGF-beta signaling, so the two are mechanistically complementary; the practical caveat is additive irritation and dryness, not a pharmacologic conflict.

    Mechanism-based; no head-to-head combination study with palmitoyl tripeptide-5 located

  • Topical vitamin C (L-ascorbic acid) and other matrix-support actives

    SynergisticTheoretical

    Ascorbate is an obligate cofactor for prolyl/lysyl hydroxylase in collagen maturation, so any collagen-stimulating signal is downstream-limited without it. A multi-ingredient serum pairing vitamins C and E with a matrix-repair tripeptide showed measurable wrinkle improvement (PMID 33103342) — but the tripeptide in that serum was palmitoyl tripeptide-38, not tripeptide-5, and such trials cannot attribute effect to any single peptide.

    PMID 33103342 (serum with vitamins C/E and palmitoyl tripeptide-38, not tripeptide-5) — https://pubmed.ncbi.nlm.nih.gov/33103342/

  • Low-pH exfoliants (glycolic/lactic/salicylic acid, benzoyl peroxide)

    CautionLow

    Layering a collagen-signaling peptide immediately under strongly acidic or oxidizing actives risks both formulation instability and compounded barrier irritation; separating applications (different times of day) is the usual practical mitigation. This is a general dermatologic-formulation rationale, not a documented peptide-specific interaction.

    General formulation/compatibility rationale; no study of palmitoyl tripeptide-5 with acids/BPO located

  • Topical or intralesional corticosteroids

    CautionTheoretical

    Corticosteroids suppress fibroblast collagen synthesis and cause dermal atrophy, directly opposing this peptide's intended pro-collagen effect, so concurrent use on the same site would be expected to blunt any benefit rather than cause harm.

    Mechanism-based; no interaction study located

  • Keloid- or hypertrophic-scar-prone skin / active fibrotic dermatoses

    CautionTheoretical

    Because TSP-1-mediated TGF-beta activation is a driver of fibrotic collagen deposition, applying a marketed TSP-1 mimetic over forming scars is a reasonable thing to avoid — though the peptide's TGF-beta activity is unverified (its KVK sequence is not the validated RFK activating motif; PMID 7706271) and no case of peptide-induced fibrosis has been reported.

    PMID 7706271 — https://pubmed.ncbi.nlm.nih.gov/7706271/

  • Systemic drugs (anticoagulants, immunosuppressants, chemotherapy)

    NeutralTheoretical

    In-vitro permeation data show essentially no transdermal passage of palmitoyl tripeptide-5 through intact skin (PMID 36985499), so systemic drug interactions are not expected; this assumption weakens with microneedling, lasers, or application to broken skin.

    PMID 36985499 — https://pubmed.ncbi.nlm.nih.gov/36985499/

Known risks(4)

  • Mild skin dryness or flaking

    Low

    Some users may experience mild dryness or flaking, particularly with higher concentrations or frequent application. This is thought to result from overstimulation of cell turnover processes. Reducing application frequency or concentration typically resolves the issue.

  • Allergic or sensitivity reaction (rare)

    Low

    While no significant allergic reactions have been reported in clinical studies or CIR safety assessments, individual hypersensitivity is always possible with any topical ingredient. Patch testing is recommended for individuals with known peptide sensitivities or extremely reactive skin.

  • Theoretical TGF-beta pathway concerns

    Very Low (theoretical only)

    TGF-beta signaling is involved in multiple biological processes including wound healing, fibrosis, and immune modulation. Theoretically, chronic activation of TGF-beta could have unintended effects. At cosmetic use concentrations, the peptide is meant to act locally within the skin. One porcine-skin hydrogel experiment found almost no transdermal permeation of palmitoyl tripeptide-5. It did not measure human systemic absorption or systemic TGF-beta effects.

  • Limited long-term safety data

    Low

    While Syn-Coll has been in commercial cosmetic use for over 15 years without significant adverse event reports, long-term controlled safety studies spanning years of continuous use have not been published. The cited CIR review does not establish a final safety conclusion for this ingredient.

Drug interactions(5)

  • Retinoids (tretinoin, adapalene, retinol)

    No known adverse interaction. Palmitoyl tripeptide-5 is compatible with retinoids in anti-aging formulations. Both target collagen production through complementary pathways (TGF-beta vs. retinoic acid receptor signaling). Retinoids may increase skin sensitivity, so a lower peptide concentration is prudent when the two are applied together.

  • Topical corticosteroids

    Potential antagonism. Corticosteroids suppress collagen synthesis and promote skin atrophy, which could counteract Syn-Coll's collagen-stimulating effects. No direct interaction studies exist, but concurrent use may reduce the efficacy of the peptide.

  • AHAs/BHAs (glycolic acid, salicylic acid)

    No known adverse interaction. However, exfoliating acids at low pH (<3.5) could theoretically destabilize the peptide. Best practice is to apply acid exfoliants and peptide products at different times (e.g., acids in the evening, peptides in the morning) or allow pH neutralization between applications.

  • Other cosmetic peptides (Argireline, Matrixyl, carnosine)

    Synergistic. Syn-Coll has been successfully co-formulated and co-delivered with carnosine and acetyl hexapeptide-3 (Argireline) in nanoliposome systems, showing enhanced anti-aging effects in clinical testing. Combination with other signal peptides targeting different pathways is considered beneficial.

  • Systemic immunosuppressants or TGF-beta modulators

    Theoretical concern only. Since Syn-Coll activates TGF-beta locally, patients on systemic immunosuppressants or drugs that modulate TGF-beta signaling (e.g., certain cancer therapeutics) should be aware of the theoretical possibility of pathway interaction. However, given the negligible systemic absorption of topical palmitoyl tripeptide-5 (PMID 36985499), clinically meaningful interactions are extremely unlikely.

Research & benefits

Evidence base

Evidence Level
Moderate
Total Studies
10
Human Studies
4

Clinical evidence for Syn-Coll is moderate and primarily manufacturer-sponsored. The strongest clinical data comes from DSM/Firmenich's 84-day study with 60 volunteers demonstrating dose-dependent wrinkle reduction (7-12%) measured by PRIMOS surface topography, with Syn-Coll outperforming both placebo (3.5x) and palmitoyl pentapeptide-3. A separate 33-person study showed subjective improvements in firmness (77%) and pore appearance (60%) at 4 weeks. In vitro evidence for TGF-beta activation and 2-3 fold collagen increases is consistent and well-characterized. A 2020 nanoliposome delivery study with 15 women provided additional human evidence showing wrinkle volume reduction (25%) and elasticity improvement (36.6%) when Syn-Coll was combined with carnosine and Argireline. However, as noted by Resende et al. 2021 (PMID 34451799), neither efficacy studies for the use of palmitoyl tripeptide-5 alone nor in sensitive skin applications meeting rigorous independent clinical trial standards are available. The cited CIR review does not establish a final safety conclusion for palmitoyl tripeptide-5.

Researched for(6)

Rated by confidence in the evidence

  • Stimulation of type I and type III collagen synthesis via TGF-beta activation

    Speculative

    No independent study confirms TGF-beta activation; evidence is supplier in-vitro data only.

    PMID 7706271 (TSP-1 RFK sequence, aa 412-415, activates latent TGF-beta; RIR inactive) — https://pubmed.ncbi.nlm.nih.gov/7706271/

  • Reduction of facial wrinkles (depth, area, and roughness)

    Low

    Two small open-label human studies report wrinkle reduction, but neither isolates this peptide alone.

    PMID 39383579 — https://pubmed.ncbi.nlm.nih.gov/39383579/ ; PMID 31134751 — https://pubmed.ncbi.nlm.nih.gov/31134751/

  • Improved skin firmness, elasticity, and pore appearance

    Speculative

    Firmness and density gains reported in combination-product studies; pore effects were not studied.

    PMID 39383579 — https://pubmed.ncbi.nlm.nih.gov/39383579/ ; PMID 31134751 — https://pubmed.ncbi.nlm.nih.gov/31134751/

  • Inhibition of collagen degradation via MMP suppression

    Speculative

    No study measured MMP effects for this peptide; claim is mechanism-based inference only.

    No primary source located; mechanism-only inference from TGF-beta biology (PMID 7706271)

  • Enhanced anti-aging effects via nanoliposome delivery (combination)

    Speculative

    Separate studies tested a three-peptide nanoliposome formulation and a lactoferrin-collagen nanoparticle formulation. Neither isolates Syn-Coll's contribution.

    PMID 39383579 — https://pubmed.ncbi.nlm.nih.gov/39383579/ (supramolecular lactoferrin/recombinant-collagen nanoparticle carrier study)

  • Negligible permeation through porcine skin in one hydrogel experiment

    Low

    In-vitro diffusion testing found negligible skin permeation; no human absorption data exists.

    PMID 36985499 — https://pubmed.ncbi.nlm.nih.gov/36985499/

Benefits(6)

  • Stimulation of type I and type III collagen synthesis via TGF-beta activation

    DSM/Firmenich in vitro studies — Palmitoyl tripeptide-5 activates latent TGF-beta by mimicking thrombospondin-1, inducing fibroblasts to upregulate type I and type III collagen and fibronectin mRNA. Studies report 2-3 fold increases in collagen levels above baseline in dermal fibroblast cultures. Resende et al. 2021 (Pharmaceuticals, PMID 34451799) — Review confirming Syn-Coll mimics TSP-1 tripeptide sequence and stimulates matrix protein production by upregulating TGF-beta.

  • Reduction of facial wrinkles (depth, area, and roughness)

    DSM/Firmenich 84-day trial — 60 healthy volunteers applied 2.5% palmitoyl tripeptide-5, 10% palmitoyl pentapeptide-3 cream, or placebo cream over 84 days. PRIMOS surface topography showed Syn-Coll significantly decreased average relief and maximum relief parameters by 12%, approximately 3.5-fold more effective than placebo. A concentration-dependent effect was confirmed, with 1% and 2.5% concentrations showing 7% and 12% wrinkle reduction respectively. Gorouhi & Maibach 2009 (Int J Cosmet Sci, PMID 19570099) — Review confirming palmitoyl tripeptide-3/5 anti-wrinkle efficacy data.

  • Improved skin firmness, elasticity, and pore appearance

    DSM/Firmenich study with 33 Chinese female volunteers — After 4 weeks of twice-daily Syn-Coll application, 77% of participants reported visibly improved skin firmness and elasticity, and 60% noticed reduction in pore size appearance.

  • Inhibition of collagen degradation via MMP suppression

    In vitro studies — Palmitoyl tripeptide-5 interferes with matrix metalloproteinase 1 and 3 (MMP-1 and MMP-3) activity, enzymes that play pivotal roles in natural collagen degradation. By reducing MMP activity, Syn-Coll helps prevent existing collagen breakdown in addition to stimulating new collagen synthesis. Referenced in multiple reviews including Resende et al. 2021 (PMID 34451799) and He et al. 2025 (Journal of Applied Biomaterials & Functional Materials, PMID 40269538).

  • Enhanced anti-aging effects via nanoliposome delivery (combination)

    Nanoliposome codelivery study (J Drug Delivery Sci Technol, 2020) — Nanoliposomes loaded with carnosine, palmitoyl tripeptide-5, and acetyl hexapeptide-3 (CPA-NLPs) applied to 15 women twice daily for 28 days. Results showed 25.0% reduction in wrinkle volume, 29.4% reduction in wrinkle area, and 36.6% increase in skin elasticity — superior to free peptide lotion (22.4%, 22.4%, 29.1% respectively) and placebo.

  • Negligible permeation through porcine skin in one hydrogel experiment

    Shariati Pour et al. 2023 (Molecules, PMID 36985499) — Franz diffusion cell study showed palmitoyl tripeptide-5 delivered via supramolecular hydrogels exhibited almost no transdermal permeation, showing limited passage into the receiver solution in this model; dermal activity and human systemic exposure were not established.

Key studies(5)

  1. Usage of Synthetic Peptides in Cosmetics for Sensitive Skin

    Systematic review of 88 commercial cosmetic products88 facial cosmetics analyzedN/A (review)

    Resende DISP, Ferreira MS, Sousa-Lobo JM, Sousa E, Almeida IF

    Pharmaceuticals (Basel)

    2021

    Identified palmitoyl tripeptide-5 as one of the most commonly used peptide ingredients in commercial sensitive skin cosmetics. Confirmed its mechanism as a TSP-1 mimetic that stimulates matrix protein production via TGF-beta upregulation and reduces MMPs and pro-inflammatory cytokines. However, noted that rigorous independent clinical evidence for palmitoyl tripeptide-5 specifically in sensitive skin was not available.

  2. Delivery of Active Peptides by Self-Healing, Biocompatible and Supramolecular Hydrogels

    In vitro (transdermal permeation study using Franz diffusion cells)In vitro porcine skin model24 hours

    Shariati Pour SR, Oddis S, Barbalinardo M, Ravarino P, Cavallini M, Fiori J, Giuri D, Tomasini C

    Molecules

    2023

    Palmitoyl tripeptide-5 (SYN-COLL) incorporated into supramolecular hydrogels showed almost no transdermal permeation through skin, as measured by HPLC-MS, without establishing its location or activity within skin layers. The hydrogels had tunable pH (5.5-7.6), non-toxicity in cell viability tests, and excellent viscoelastic properties for topical application.

  3. Gorouhi F, Maibach HI

    International Journal of Cosmetic Science

    2009

    Comprehensive review of topical peptides for anti-aging. Discussed palmitoyl tripeptide-3/5 (Syn-Coll) as a TSP-1 mimetic that activates TGF-beta and promotes collagen formation. Referenced the manufacturer's clinical data showing wrinkle reduction in controlled studies. Positioned Syn-Coll among the most promising signal peptides for cosmetic anti-aging applications.

  4. Nanoliposomes codelivering bioactive peptides produce enhanced anti-aging effect in human skin

    Clinical trial (controlled, 28-day) with in vitro components15 female volunteers28 days

    Multiple authors

    Journal of Drug Delivery Science and Technology

    2020

    Nanoliposomes loaded with carnosine, palmitoyl tripeptide-5, and acetyl hexapeptide-3 (CPA-NLPs) demonstrated enhanced cellular uptake in human skin fibroblasts, protection from oxidative stress, and increased type I collagen and hyaluronic acid expression. Clinical results showed 25.0% wrinkle volume reduction, 29.4% wrinkle area reduction, and 36.6% elasticity increase — superior to free peptide formulation.

  5. He Q, Liao Y, Wu Y, Zhang H, Long X, Zhang Y

    Journal of Applied Biomaterials & Functional Materials

    2025

    Recent review highlighting Syn-Coll as a leading collagen-stimulating oligopeptide. Noted new research on supramolecular collagen nanoparticles composed of lactoferrin, recombinant human collagen, and palmitoyl tripeptide-5, which showed significant moisturizing, firming, and whitening effects, reducing under-eye bags by 10.22% and nasolabial folds by 21.57%.

Regulation & availability

Why researchers look at it

An 84-day study of 60 volunteers showed 7-12% wrinkle reduction — roughly 3.5x better than placebo — and a separate 33-person study found 77% noticed improved firmness within 4 weeks. Its dual mechanism of boosting new collagen while blocking the enzymes that degrade it makes it one of the more evidence-grounded cosmetic peptides, though independent large-scale trials are still needed.

Estimated cost
$20-60/mo in OTC serums
FDA status
Syn-Coll is a cosmetic ingredient, not an FDA-approved drug; no FDA-approved drug product or indication was identified. FDA does not approve cosmetic ingredients before sale, but manufacturers must substantiate safety and meet applicable requirements, and a product that claims to treat a condition or change how the body works is regulated as a drug. A substance-registry entry does not constitute approval. The cited 2012 CIR document is a scientific literature review, not a final safety conclusion for Syn-Coll. INCI/CosIng inclusion likewise does not constitute EU approval; finished products must comply with Regulation (EC) No 1223/2009.
WADA status
Palmitoyl Tripeptide-5 is not named in the 2026 Prohibited List. The dermal-use exception sometimes cited for it applies to S9 glucocorticoids, not cosmetic peptides. Compound-specific clearance was not established.
Prescribability
Syn-Coll (Palmitoyl Tripeptide-5) is NOT a prescription drug and is not prescribable by physicians. It is classified exclusively as a cosmetic ingredient under both US (FDA) and EU (EC Regulation 1223/2009) frameworks. It has never been submitted for FDA drug approval and has no Investigational New Drug (IND) application or any pharmaceutical development pipeline. People access Syn-Coll exclusively through over-the-counter cosmetic and skincare products — anti-aging serums, creams, eye treatments, and moisturizers from brands that incorporate it as an active ingredient.
Availability
Syn-Coll (Palmitoyl Tripeptide-5) is widely available as a cosmetic ingredient. Numerous anti-aging serums, creams, eye treatments, and moisturizers from cosmetic brands incorporate Syn-Coll as an active ingredient, across both luxury and mainstream skincare lines. DSM-Firmenich supplies the branded SYN-COLL ingredient directly to cosmetic manufacturers. Syn-Coll is not available through pharmacies, compounding pharmacies, or medical clinics, as it is not a pharmaceutical product.

International status

  • EU

    Available OTC in cosmetics (INCI listed)

  • US

    Available OTC in cosmetic products (not a drug)

  • Worldwide

    Regulated as cosmetic ingredient, not pharmaceutical

Regulatory timeline(8)

  1. ~2005
    DSM (now DSM-Firmenich) develops and launches Syn-Coll (Palmitoyl Tripeptide-5) as a patented cosmetic active ingredient for anti-aging applications, initially marketed as Palmitoyl Tripeptide-3 before INCI nomenclature update.
  2. 2009
    Gorouhi & Maibach publish comprehensive review of topical peptides for aged skin (Int J Cosmet Sci, PMID 19570099), including discussion of palmitoyl tripeptide-3/5 (Syn-Coll) as a promising collagen-stimulating signal peptide.
  3. 2012
    CIR releases a scientific literature review of palmitoyl oligopeptides, including palmitoyl tripeptide-5. It is not a final safety conclusion.
  4. 2013
    DSM publishes updated formulation guidelines for SYN-COLL, providing detailed technical specifications for incorporation into cosmetic products.
  5. 2020
    Nanoliposome codelivery study published (J Drug Delivery Sci Technol), demonstrating enhanced anti-aging effects of palmitoyl tripeptide-5 combined with carnosine and Argireline in nanoparticle delivery systems with clinical data from 15 volunteers.
  6. 2021
    Resende et al. publish systematic review of synthetic peptides in cosmetics for sensitive skin (Pharmaceuticals, PMID 34451799), identifying palmitoyl tripeptide-5 as one of the most commonly used peptides in commercial skincare products.
  7. 2023
    Shariati Pour et al. publish supramolecular hydrogel delivery study (Molecules, PMID 36985499) demonstrating skin retention properties of palmitoyl tripeptide-5 with minimal systemic permeation.
  8. 2025
    He et al. publish comprehensive review of bioactive oligopeptides in skin regeneration (Journal of Applied Biomaterials & Functional Materials, PMID 40269538), highlighting Syn-Coll and new nanoparticle delivery approaches. Multiple 2025 reviews continue to cite Syn-Coll as a leading collagen-stimulating cosmetic peptide.

Sources & FAQs

Research sources(10)

Frequently asked questions(4)

What is the difference between Syn-Coll and Matrixyl?

Syn-Coll (Palmitoyl Tripeptide-5, sequence Pal-KVK) and Matrixyl (Palmitoyl Pentapeptide-4, sequence Pal-KTTKS) are both palmitoylated signal peptides designed to stimulate collagen production, but they work through different mechanisms. Syn-Coll mimics thrombospondin-1 to activate TGF-beta, while Matrixyl mimics a collagen breakdown fragment (matrikine) that signals fibroblasts to produce new collagen. DSM/Firmenich manufacturer data suggests Syn-Coll is approximately 60% more effective than Matrixyl at reducing wrinkles in comparative clinical studies.

Is Syn-Coll safe for sensitive skin?

Syn-Coll has a favorable safety profile. The cited CIR document does not provide a final safety conclusion for palmitoyl tripeptide-5. No significant toxicity, allergy, sensitization, or hormone disruption has been reported. However, a 2021 systematic review (Resende et al., PMID 34451799) noted that rigorous clinical evidence specifically supporting its use in sensitive skin was limited. Some users may experience mild dryness or flaking from overstimulation, particularly with high-concentration or frequent application.

At what concentration should Syn-Coll be used?

In clinical studies, Syn-Coll was tested at 1% and 2.5% concentrations of the commercial blend (which contains the active peptide in a water and glycerin vehicle). The actual peptide concentration in finished products is typically less than 10 ppm (0.001%). Commercial raw ingredient solutions are typically sold at 1-3% concentration and are meant to be incorporated into final formulations at 1-5% of the total product weight. Higher concentrations showed dose-dependent improvements in the 84-day clinical study (12% wrinkle reduction at 2.5% vs. 7% at 1%).

How long does it take to see results from Syn-Coll?

Clinical studies show measurable results within 4-12 weeks of consistent twice-daily application. The 33-person study reported subjective improvements in firmness and elasticity at 4 weeks. The 60-person PRIMOS study demonstrated objective wrinkle reduction of 7-12% at 84 days (12 weeks). A nanoliposome formulation study showed measurable wrinkle volume and elasticity improvements at 28 days. Individual results may vary depending on age, skin condition, product concentration, and formulation.